Patient Partner Capital is an early-stage venture fund embedded in the Boston biotech ecosystem, investing in women's health therapeutics, diagnostics, and platform technologies from pre-seed through Series A, integrating patient-derived evidence into investment decisions before capital is deployed.
We think about women's health as three distinct categories: conditions specific to women, conditions that show up differently in women, and conditions where women carry a disproportionate share of the burden. We built Patient Partner Capital to invest across all three, using patient-derived evidence as part of how we evaluate companies. We focus on therapeutics, diagnostics, and platform technologies, evaluating each opportunity with the same rigor biopharma applies to its own pipeline decisions.
Conditions specific to women.
Conditions that manifest differently in women.
Conditions manifested disproportionately in women.
Patient-centricity is now standard across biopharma. We take it one step further.
At Patient Partner Capital, patient-derived evidence is integrated into diligence and underwriting before capital is deployed — an execution model that is designed to improve the probability of success of biotech.
Women's health VC investment reached $2.6B in 2024, up 55% year-over-year — and biopharma's share of that capital nearly tripled, from 12% (2021) to 34% (2024), as the category shifts from consumer health apps toward drug development itself.
Scientific advances, growing pharmaceutical demand, and increased attention to women's health are creating new opportunities for therapeutic innovation.
Biotech executive, operator and angel investor with 20+ years across large biopharma, mid-sized healthcare, and early-stage startups.
LinkedIn ↗
Biotech executive with 20 years across large and mid-sized biopharma and early-stage startups.
LinkedIn ↗